The role of the mTOR pathway in regulating food intake

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 5, 2010, Pages 604-612

  Wiczer, Brain M ^a   Thomas, George ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Amino acid; ghrelin; glucose; hypothalamus; leptin; leucine; mTOR; obesity

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 OXOISOCAPROIC ACID; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENYLATE KINASE; AMINO ACID; FATTY ACID; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INITIATION FACTOR 4E BINDING PROTEIN; INSULIN; INTERLEUKIN 6; LEPTIN; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PEPTIDE YY; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROLINE RICH PROTEIN; RAPAMYCIN; S6 KINASE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ANOREXIA; BRAIN; FATTY ACID SYNTHESIS; FEEDING; FOOD INTAKE; GASTROINTESTINAL TRACT; GLUCONEOGENESIS; HORMONE RELEASE; HUMAN; HYPOTHALAMUS; NONHUMAN; NUTRIENT; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANOREXIA; APPETITE REGULATION; HUMANS; HYPOTHALAMUS; NUTRITIONAL STATUS; OBESITY; SIGNAL TRANSDUCTION; STOMACH; TOR SERINE-THREONINE KINASES;

EID: 77956399070     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Menon S, Manning BD: Common corruption of the mTOR signaling network in human tumors. Oncogene (2008) 27 (Suppl 2):S43-S51.
2. Hunter T: When is a lipid kinase not a lipid kinase? When it is a protein kinase. Cell (1995) 83(1):1-4.
3. Heitman J, Movva NR, Hall MN: Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science (1991) 253(5022):905-909.
4. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 110(2):163-175.
5. Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, Sabatini DM: GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 11(4):895-904.
6. Thedieck K, Polak P, Kim ML, Molle KD, Cohen A, Jeno P, Arrieumerlou C, Hall MN: PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One (2007) 2(11):e1217.
7. Oshiro N, Takahashi R, Yoshino K, Tanimura K, Nakashima A, Eguchi S, Miyamoto T, Hara K, Takehana K, Avruch J, Kikkawa U et al: The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem (2007) 282(28):20329-20339.
8. Wang L, Harris TE, Roth RA, Lawrence JC Jr: PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem (2007) 282(27):20036-20044.
9. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM: PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 25(6):903-915.
10. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 14(14):1296-1302.
11. J acinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B: Sin1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell (2006) 127(1):125-137.
12. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 307(5712):1098-1101.
13. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J: Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem (1998) 273(23):14484-14494.
14. Sharma S, Guthrie PH, Chan SS, Haq S, Taegtmeyer H: Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc Res (2007) 76(1):71-80.
15. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A et al: Metformin, independent of AMPK, inhibits mTORC1 in a Rag GTPase-dependent manner. Cell Metab (2010) 11(5):390-401.
16. Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD, Pearson RB: Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors (2007) 25(4):209-226.
17. Mieulet V, Roceri M, Espeillac C, Sotiropoulos A, Ohanna M, Oorschot V, Klumperman J, Sandri M, Pende M: S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover. Am J Physiol Cell Physiol (2007) 293(2):C712-C722.
18. Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG: Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J (2001) 20(16):4370-4379.
19. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M: S6K1- and βTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science (2006) 314(5798):467-471.
20. Tuxworth WJ Jr, Saghir AN, Spruill LS, Menick DR, McDermott PJ: Regulation of protein synthesis by eIF4E phosphorylation in adult cardiocytes: The consequence of secondary structure in the 5'-untranslated region of mRNA. Biochem J (2004) 378(Pt 1):73-82.
21. Fonseca BD, Smith EM, Lee VH, MacKintosh C, Proud CG: PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem (2007) 282(34):24514-24524.
22. Ganley IG, Lam du H, Wang J, Ding X, Chen S, Jiang X: ULK1.ATG13. FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem (2009) 284(18):12297-12305.
23. Jung CH, Jun CB, Ro SH, Kim YM, Otto NM, Cao J, Kundu M, Kim DH: ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell (2009) 20(7):1992-2003.
24. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J: Rheb binds and regulates the mTOR kinase. Curr Biol (2005) 15(8):702-713.
25. Edinger AL, Thompson CB: Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell (2002) 13(7):2276-2288.
26. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP: Phosphorylation and functional inactivation of TSC2 by ERK implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 121(2):179-193.
27. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J: Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA (2004) 101(37):13489-13494.
28. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C, Myer VE et al: Bidirectional transport of amino acids regulates mTOR and autophagy. Cell (2009) 136(3):521-534.
29. Gulati P, Gaspers LD, Dann SG, Joaquin M, Nobukuni T, Natt F, Kozma SC, Thomas AP, Thomas G: Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell Metab (2008) 7(5):456-465.
30. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM: The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science (2008) 320(5882):1496-1501.
31. Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL: Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol (2008) 10(8):935-945.
32. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM: Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell (2010) 141(2):290-303.
33. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G: Mammalian TOR: A homeostatic ATP sensor. Science (2001) 294(5544):1102-1105.
34. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell (2008) 30(2):214-226.
35. Desai BN, Myers BR, Schreiber SL: FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc Natl Acad Sci USA (2002) 99(7):4319-4324.
36. Konner AC, Klockener T, Bruning JC: Control of energy homeostasis by insulin and leptin: Targeting the arcuate nucleus and beyond. Physiol Behav (2009) 97(5):632-638.
37. Lee MJ, Fried SK: Multilevel regulation of leptin storage, turnover, and secretion by feeding and insulin in rat adipose tissue. J Lipid Res (2006) 47(9):1984-1993.
38. Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC, Seeley RJ: Hypothalamic mTOR signaling regulates food intake. Science (2006) 312(5775):927-930.
39. Morton GJ, Blevins JE, Kim F, Matsen M, Figlewicz DP: The action of leptin in the ventral tegmental area to decrease food intake is dependent on JAK-2 signaling. Am J Physiol Endocrinol Metab (2009) 297(1):E202-E210.
40. Ghilardi N, Skoda RC: The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol Endocrinol (1997) 11(4):393-399.
41. Niswender KD, Morton GJ, Stearns WH, Rhodes CJ, Myers MG Jr, Schwartz MW: Intracellular signalling. Key enzyme in leptin-induced anorexia. Nature (2001) 413(6858):794-795.
42. Karra E, Batterham RL: The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol (2010) 316(2):120-128.
43. Blouet C, Ono H, Schwartz GJ: Mediobasal hypothalamic p70 S6 kinase 1 modulates the control of energy homeostasis. Cell Metab (2008) 8(6):459-467.
44. Kahn BB, Alquier T, Carling D, Hardie DG: AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab (2005) 1(1):15-25.
45. Minokoshi Y, Shiuchi T, Lee S, Suzuki A, Okamoto S: Role of hypothalamic AMP-kinase in food intake regulation. Nutrition (2008) 24(9):786-790.
46. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferre P, Birnbaum MJ, Stuck BJ et al: AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature (2004) 428(6982):569-574.
47. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J et al: A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab (2009) 9(4):311-326.
48. Arciero PJ, Gentile CL, Pressman R, Everett M, Ormsbee MJ, Martin J, Santamore J, Gorman L, Fehling PC, Vukovich MD, Nindl BC: Moderate protein intake improves total and regional body composition and insulin sensitivity in overweight adults. Metabolism (2008) 57(6):757-765.
49. Blouet C, Jo YH, Li X, Schwartz GJ: Mediobasal hypothalamic leucine sensing regulates food intake through activation of a hypothalamus-brainstem circuit. J Neurosci (2009) 29(26): 8302-8311.
50. He W, Lam TK, Obici S, Rossetti L: Molecular disruption of hypothalamic nutrient sensing induces obesity. Nat Neurosci (2006) 9(2):227-233.
51. Proulx K, Cota D, Woods SC, Seeley RJ: Fatty acid synthase inhibitors modulate energy balance via mammalian target of rapamycin complex 1 signaling in the central nervous system. Diabetes (2008) 57(12):3231-3238.
52. Kim EK, Miller I, Aja S, Landree LE, Pinn M, McFadden J, Kuhajda FP, Moran TH, Ronnett GV: C-75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J Biol Chem (2004) 279(19):19970-19976
53. Stolarczyk E, Guissard C, Michau A, Even PC, Grosfeld A, Serradas P, Lorsignol A, Penicaud L, Brot-Laroche E, Leturque A, Le Gall M: Detection of extracellular glucose by GLUT2 contributes to hypothalamic control of food intake. Am J Physiol Endocrinol Metab (2010) 298(5):E1078-E1087
54. Potier M, Darcel N, Tome D: Protein, amino acids and the control of food intake. Curr Opin Clin Nutr Metab Care (2009) 12(1):54-58.
55. Batterham RL, Heffron H, Kapoor S, Chivers JE, Chandarana K, Herzog H, Le Roux CW, Thomas EL, Bell JD, Withers DJ: Critical role for peptide YY in protein-mediated satiation and bodyweight regulation. Cell Metab (2006) 4(3):223-233.
56. Bowen J, Noakes M, Clifton PM: Appetite regulatory hormone responses to various dietary proteins differ by body mass index status despite similar reductions in ad libitum energy intake. J Clin Endocrinol Metab (2006) 91(8):2913-2919.
57. Lejeune MP, Westerterp KR, Adam TC, Luscombe-Marsh ND, Westerterp-Plantenga MS: Ghrelin and glucagon-like peptide 1 concentrations, 24-h satiety, and energy and substrate metabolism during a high-protein diet and measured in a respiration chamber. Am J Clin Nutr (2006) 83(1):89-94.
58. Xu G, Li Y, An W, Li S, Guan Y, Wang N, Tang C, Wang X, Zhu Y, Li X, Mulholland MW et al: Gastric mammalian target of rapamycin signaling regulates ghrelin production and food intake. Endocrinology (2009) 150(8):3637-3644.
59. Greenfield JR, Farooqi IS, Keogh JM, Henning E, Habib AM, Blackwood A, Reimann F, Holst JJ, Gribble FM: Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr (2009) 89(1):106-113.
60. Chen Q, Reimer RA: Dairy protein and leucine alter GLP-1 release and mRNA of genes involved in intestinal lipid metabolism in vitro. Nutrition (2009) 25(3):340-349.
61. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature (1999) 402(6762):656-660.
62. Castaneda TR, Tong J, Datta R, Culler M, Tschop MH: Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol (2010) 31(1):44-60.
63. Le Bacquer O, Petroulakis E, Paglialunga S, Poulin F, Richard D, Cianflone K, Sonenberg N: Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest (2007) 117(2):387-396.
64. Carnevalli LS, Masuda K, Frigerio F, Le Bacquer O, Um SH, Gandin V, Topisirovic I, Sonenberg N, Thomas G, Kozma SC: S6K1 plays a critical role in early adipocyte differentiation. Dev Cell (2010) 18(5):763-774.
65. Chang GR, Wu YY, Chiu YS, Chen WY, Liao JW, Hsu HM, Chao TH, Hung SW, Mao FC: Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in highfat diet-fed KK/HIJ mice. Basic Clin Pharmacol Toxicol (2009) 105(3):188-198.
66. Houde VP, Brule S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y, Marette A: Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes (2010) 59(6):1338-1348.
67. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, Berthault MF, Magnan C, Cerasi E, Kaiser N, Leibowitz G: mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes (2008) 57(4):945-957.
68. Ruggenenti P, Remuzzi A, Remuzzi G: Decision time for pancreatic islet-cell transplantation. Lancet (2008) 371(9616): 883-884.